companies / bonumtherapeutics-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-07 json
| total_raised | 27,000,00027.0M | ○ |
|---|---|---|
| founded | 2021 | |
| hq | SEATTLE, WA | |
| industry | unknown | |
| stage | null |
Antibody-controlled therapeutics with dual-binding antibodies that stay inactive until they encounter their target, focused on regulated cytokines. Targets oncology with extensions into autoimmune, metabolic, and pain indications. Differentiated by activity-on-binding antibody chemistry rather than payload chemistry.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2026-04-03 | Funding round | 27,000,00027.0M | null | ○ |
| fact | status | src |
|---|---|---|
| Funding round, $27.0M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |
| date | fact | change | src |
|---|---|---|---|
| 2026-09-25latest_round: seed, $27.0M, 2026-04-03 → Funding round, $27.0M, 2026-04-03, ○ 2026-05-07 | latest_round | seed, $27.0M, 2026-04-03 → Funding round, $27.0M, 2026-04-03 | ○ 2026-05-07 |
Records begin 2026-09-24. all_changes